Type 2 & other diabetes

Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials

DiabetologiaPublished Systematic review and network meta-analysis of randomised controlled trials

Authors' conclusion

Our data show that s.c. tirzepatide had a more pronounced effect on HbA1c and weight reduction compared with s.c. semaglutide in people with type 2 diabetes. Both drugs, particularly higher doses of tirzepatide, increased gastrointestinal adverse events.

Study context

Population
Adults with T2D, any background glucose-lowering treatment; RCTs ≥12 weeks (PubMed and Cochrane to 11 November 2023); 44.2% female
Participants
23,622 adults28 trials
Comparison
s.c. tirzepatide vs s.c. semaglutide
Outcome
Change in HbA1c and body weight from baseline
Methodological detailsfrequentist random-effects network meta-analysis, ROB 2 risk-of-bias assessment, Confidence In Network Meta-Analysis (CINeMA) confidence assessment
  • Frequentist random-effects network meta-analysis
  • ROB 2 risk-of-bias assessment
  • CINeMA confidence assessment

Pooled result

As reported in the abstract

Change in HbA1c vs placebo

Mean difference, mmol/mol

Tirzepatide 15 mg · −1.96%
−21.61
Tirzepatide 10 mg · −1.84%
−20.19
Semaglutide 2.0 mg · −1.59%
−17.74
Tirzepatide 5 mg · −1.60%
−17.60
Semaglutide 1.0 mg · −1.39%
−15.25
Semaglutide 0.5 mg · −1.09%
−12.00

kg

Body weight reduction vs placebo, tirzepatide 15 mg
9.57
Body weight reduction vs placebo, tirzepatide 5 mg
5.27
Body weight reduction vs placebo, semaglutide 2.0 mg
4.97
Body weight reduction vs placebo, semaglutide 0.5 mg
2.52

Safety

Both drugs increased incidence of gastrointestinal adverse events vs placebo
Neither tirzepatide nor semaglutide increased risk of serious adverse events or severe hypoglycaemia

Original publication

Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials. Diabetologia. Published 13 April 2024. doi:10.1007/s00125-024-06144-1

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.